News | July 18, 2011

Study Confirms Stent Captures Endothelial Progenitor Cells, Accelerates Re-Endothelialization

July 18, 2011 — OrbusNeich announced that data from an ex vivo arteriovenous (AV) shunt model of human circulating blood, in addition to results from three preclinical studies, demonstrated that the Genous Stent effectively captures circulating CD34+ endothelial progenitor cells (EPCs). This leads to accelerated re-endothelialization and decreased thrombogenicity compared to bare metal stents (BMS). These mechanistic data were published as an e-publication on the European Heart Journal website.

Data from the study showed that EPC deposition on the struts was enhanced by 32.5 percent compared to BMS. In addition, the expression of specific endothelial markers increased significantly compared to those on the BMS. The data also showed a significant decrease in the expression of thrombotic markers associated with Genous.

"These data demonstrate the effectiveness of the capture of CD34+ cells for endothelialization and the prevention of thrombosis," said Eric J. Duckers, M.D., Ph.D., of the Thoraxcenter at Erasmus University Medical Center in Rotterdam, Netherlands, and senior author of the publication. "This mechanism of early endothelialization supports the usage of Genous' unique EPC capture technology especially for patients who are at higher risk of thrombosis."

For the ex vivo human study, 15 patients undergoing coronary angiography received an extracorporeal femoral AV shunt containing a Genous and a BMS, which were exposed to circulating blood for up to 120 minutes. The cell depositions on the struts were determined by confocal and scanning electron microscopic (SEM) analysis. Expression of endothelial and thrombotic markers was determined using quantitative polymerase chain reaction (qPCR).

"We were able to see a significant difference between the Genous Stent and the bare metal stent in promoting EPC capture and reducing acute thrombogenicity," said Renu Virmani, M.D., of the CVPath Institute Inc. in Gaithersburg, Md., and co-author of the publication. "The Genous Stent appears to not only promote the adhesion of human EPCs, but it also reduces the adhesion of fibrin, platelets and inflammatory cells, all of which are important for the prevention of thrombus."

Further studies validating the EPC capture concept were conducted in vitro and in two animal models. An in vitro cell-capture assay demonstrated a preferential adhesion of human peripheral blood-derived CD34+ cells to Genous, with 86 percent of the attached cells positive for CD34 compared to 26 percent of cells on the BMS. In a baboon AV shunt model, the investigators showed that the stent inhibits in-stent thrombosis, as indicated by a significant increase in platelet deposition on the BMS compared to Genous. In a rabbit endothelial denudation model, qPCR analysis of endothelial marker expression indicated that it significantly promotes re-endothelialization at seven days compared to BMS.

For more information: www.orbusneich.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init